Noxopharm Ltd has released a press release.
Peer-Reviewed Publication Strengthens Case For Veyonda
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Noxopharm
- Noxopharm 2020 June quarter Appendix 4C & Activities Report
- Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
- Data Shows Idronoxil Holds Key to Problem of COLD Cancers
- COVID-19 Trial Program to Commence in Europe
- Pro-rata Non-Renounceable Rights Issue Fully Allocated
Later from Noxopharm
- Appendix 4E and Audited Financial Statements FY2020
- Veyonda COVID-19 Study Approved For Immediate Start
- First COVID-19 Patient Treated in Veyonda Study
- Noxopharm Loan Terms Amended to Benefit Company
- Noxopharm Quarterly Activities Report & Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm